Jazz Pharmaceuticals (JAZZ) 25th Annual Needham Virtual Healthcare Conference summary

Financial and operational highlights

• Achieved 21st consecutive year of revenue growth in 2025, with record revenues of $4.3 billion and strong commercial execution across a diversified portfolio.

• 2026 revenue guidance set at $4.25–$4.5 billion, targeting a 22nd year of growth, with double-digit expansion in epilepsy and oncology franchises.

• Ended last year with $2.4 billion in cash and investments, supporting ongoing business development and M&A activities.

• Recent all-time high closing stock price reflects strong momentum and investor confidence.

Strategic focus and business development

• Refined strategy centers on rare diseases within core strengths (epilepsy, oncology, sleep), with measured expansion into new rare disease areas.

• Prioritizing post-proof-of-concept or perimarket assets for initial entry into new rare disease segments, with potential for earlier-stage investments as expertise grows.

• Business development remains a key pillar, with focus on bolt-on licensing and acquisitions in the $500 million–$2.5 billion range.

• Transformation underway from specialty pharma to biotech/biopharma, with increasing emphasis on internally developed assets.

Pipeline and product updates

• XYWAV maintains a strong market position as the only low-sodium oxybate, with growth expected in idiopathic hypersomnia (IH) despite generic competition.

• Modeyso launch progressing well; peak revenue potential depends on therapy duration and patient identification, with ongoing ACTION trial to support label expansion.

• Epidiolex growth driven by Nurse Navigator program and focus on adult population; new study underway in focal onset seizures.

• JZP047, a Jazz-developed molecule for absence epilepsy, marks a shift toward internal R&D innovation.